icobrain dm


icobrain dm aims to aid physicians with the differential diagnosis of the most common dementia types: Alzheimer’s Disease (AD), vascular dementia (VaD), dementia with Lewy Bodies (DLB) and Frontotemporal dementia (FTD).

icobrain dm uncovers abnormality patterns by:
- Quantifying and tracking annualized brain volume changes of dementia-specific brain structures (frontal, parietal, temporal and hippocampal cortex).
- Comparing brain volumes and volume changes to an age-and gender-matched reference population.
- Visualizing atrophy patterns in an intuitive dementia signature.
Product specifications Information source: Vendor
Last updated: April 9, 2020
Product name icobrain dm
Company icometrix
Subspeciality Neuro
Modality MR
Disease targeted dementia
Key-features brain region quantification, report generation, brain volume changes
Suggested use During: perception aid (prompting all abnormalities/results/heatmaps), report suggestion
Data characteristics
Population MCI, dementia, Alzheimer's, FTD, DLB, ...
Input For MRI: 3D T1 weighted image
Input format DICOM
Output Color-coded segmentation overlays, concise reports with reference statistics, pre-populated radiological reporting template
Output format DICOM
Integration Integration in standard reading environment (PACS), Integration RIS (Radiological Information System), Integration via AI marketplace or distribution platform
Deployment Cloud-based
Trigger for analysis Automatically, right after the image acquisition, On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time > 10 minutes
CE Certified, Class I
FDA 510(k) cleared, Class II
Market presence
On market since 2018
Distribution channels Siemens teamplay, Blackford, Eureka Clinical AI
Countries present (clinical, non-research use) 23
Paying clinical customers (institutes) >100
Research/test users (institutes) >300
Pricing model Subscription
Based on Number of analyses
Peer reviewed papers on performance

  • Automated MRI volumetry as a diagnostic tool for Alzheimer's disease: Validation of icobrain dm (read)

Non-peer reviewed papers on performance
Other relevant papers